| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958446 | NOVEN PHARMS INC | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) | |
| US6210705 | NOVEN PHARMS INC | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
Sep, 2018
(5 years ago) | |
| US6348211 | NOVEN PHARMS INC | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
Sep, 2018
(5 years ago) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US9668981 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic based polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
Daytrana is owned by Noven Pharms Inc.
Daytrana contains Methylphenidate.
Daytrana has a total of 6 drug patents out of which 3 drug patents have expired.
Expired drug patents of Daytrana are:
- US5958446
- US6210705
- US6348211
Daytrana was authorised for market use on 06 April, 2006.
Daytrana is available in film, extended release;transdermal dosage forms.
Daytrana can be used as method for transdermally delivering a drug to a user in need thereof, for the treatment of attention deficit hyperactivity disorder (adhd).
The generics of Daytrana are possible to be released after 07 October, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 29, 2013 |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 06 April, 2006
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Method for transdermally delivering a drug to a user in need thereof
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
DAYTRANA family patents
